疗效是通过将非诺贝特加入辛伐他汀里取得的。
目的比较甘糖酯与非诺贝特的调脂疗效。
Objective To compare effect of mannose ester and fenofibrate in adjusting hyperlipdemia.
但是，受测的人口比目前的非诺贝特推荐人数大得多。
However, the population treated was broader than that recommended by current guidelines for fenofibrate.
初次截肢的风险非诺贝特组较安慰剂组降低了36%。
The risk of a first amputation was 36 percent lower among people taking fenofibrate than those taking the placebo.
与高糖组比较非诺贝特干预后能完全或部分逆转上述变化。
Compared with HG group, these changes could be fully or partly reversed by fenofibrate treatment.
目的探讨辛伐他汀联合非诺贝特治疗混合性高脂血症的价值。
Objective To discuss the val ue of simvastatin plus fenofibrate for the treatment of mixed hyperlipemia.
非诺贝特最高风险和最大受益见于伴有明显的高甘油三酯血症患者。
The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridemia.
目的湿法研磨结合挤出滚圆法制备稳定性良好的非诺贝特骨架型缓释微丸。
Objective to investigate the preparation and storage stability of the fenofibrate matrix sustained-release pellets by wet milling and extrusion-spheronization.
非诺贝特显著降低HDL胆固醇水平较低患者或高血压患者的CVD事件。
Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension.
结论：该法操作简便，结果可靠，适用于非诺贝特酸家兔血药浓度的测定。
CONCLUSIONS This method is sensitive with constant result and rapid for determining fenofibric acid concentration in rabbits plasma.
研究还发现非诺贝特组踝以下截肢风险降低47%，所截肢内无大血管病变。
The study also found that people in the fenofibrate group had a 47 percent lower risk of amputations below the ankle and without large-vessel disease in the amputated limb.
研究发现踝以上截肢风险在服用非诺贝特组和非服用非诺贝特组之间并无显著差异。
The study found virtually no difference in the risk for amputations above the ankle between those who did and did not take fenofibrate.
在ACCORD脂质研究基金会，非诺贝特同时降低了微观及宏观尿蛋白量，二者都是胰岛肾病的标志。
In ACCORD Lipid, fenofibrate also reduced micro - and macro-albuminuria, markers of diabetic renal disease.
结论：非诺贝特能抑制高糖培养的系膜细胞增殖，减少胞外基质合成，增加胞外基质的降解。
Conclusion: Fenofibrate can inhibit high glucose-induced proliferation of mesangial cells, decrease synthesis of extracellular matrix, and increase degradation of extracellular matrix.
这项研究同样证实将非诺贝特加入辛伐他汀不会引起任何肌病(肌肉病变)，静脉血栓或胰脏炎等多余危害。
The study also confirmed that adding fenofibrate to simvastatin did not result in any excess risk of myopathy (muscle problems), venous thrombosis or pancreatitis.
非诺贝特和烟酸对非酒精脂肪肝患者肝内甘油三酯含量，极低密度脂蛋白动力学，胰岛素活性的影响。
Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease.
非诺贝特可以抑制adma诱导人脐静脉内皮细胞所致MMP - 9的表达增加并促进NO的合成。
Fenofibrate reversed the effect of ADMA on the expression of MMP-9 and promoted the synthesis of no.
PEG4000十烷硫酸钠体，溶剂-熔融制备非诺贝特固体散体，再适辅混合压片制非诺贝特固体散片。
Fenofibrate solid dispersion tablets were prepared by solvent melting method using PEG4000 and sodium lauryl sulfate.
可能在今年晚些时候我们能从ACCORD试验中得到一些数据，这个试验是研究是有关糖尿病患者非诺贝特的使用。
Now, we may get that data later this year from the ACCORD trial which is studying fenofibrate in diabetics.
可能在今年晚些时候我们能从ACCORD试验中得到一些数据，这个试验是研究是有关糖尿病患者非诺贝特的使用。
Now, we may get that data later this year from the ACCORD trial which is studying fenofibrate in diabetics.
应用推荐